Bronchiolitis Obliterans Syndrome Market

Table of Content

1. INTRODUCTION
   1. Study Assumptions and Market Definition
   2. Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
   1. Market Overview
   2. Market Drivers
      1. Increasing Prevalence of Lung Transplantation Procedures and Stem Cell Transplants
   3. Market Restraints
      1. Limited Treatment Alternatives
      2. Challenges in Diagnosis and Monitoring
   4. Market Opportunity
      1. Development of Targeted Therapies and Precision Medicine to Address the Underlying Inflammatory and Fibrotic Processes
   5. Market Trends
      1. Emphasis on Research and Development
      2. Collaborations and Partnerships
5. MARKET SEGMENTATION
   1. By Drug Class
      1. Immunosuppressive Agents
      2. Azithromycin
      3. Inhaled Fluticasone
      4. Oral Montelukast
      5. Corticosteroids and Cytotoxic Agents
      6. Others
   2. By Symptoms
      1. Breath
      2. Dry Cough
      3. Respiratory Illness
      4. Others
   3. By Diagnosis
      1. Chest CT scan
      2. Pulmonary Infection Test
      3. Chest X Ray
      4. Pulmonary Function Test
   4. By Treatment
      1. Lung Transplant
      2. Drugs
      3. Others
   5. By End User
      1. Hospitals
      2. Clinics
      3. Diagnostic Centers
      4. Others
   6. By Key Geographic Regions
      1. North America
         1. United States
         2. Canada
         3. Mexico
      2. Europe
         1. Germany
         2. United Kingdom
         3. France
         4. Italy
         5. Spain
         6. Rest of Europe
      3. Asia Pacific
         1. China
         2. Japan
         3. India
         4. Australia
         5. South Korea
         6. Rest of Asia Pacific
      4. Middle East and Africa
         1. GCC
         2. South Africa
         3. Rest of Middle East and Africa
      5. South America
         1. Brazil
         2. Argentina
         3. Rest of South America
6. COMPETITIVE LANDSCAPE
   1. Company Profile
      1. AstraZeneca
      2. Allergan
      3. Cipla Inc.
      4. Endo International plc
      5. GlaxoSmithKline plc.
      6. Johnson & Johnson Private Limited
      7. Lily
      8. Merck KGaA
      9. Novartis AG
      10. Pfizer Inc.
      11. Purdue Pharma L.P.
      12. Sanofi
      13. Sumitomo Corporation
      14. Teva Pharmaceutical Industries Ltd.

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

Frequently Asked Questions

Q.1. What is the projected market value of the global bronchiolitis obliterans syndromemarket?

The global market of bronchiolitis obliterans syndromeis projected to reach USD 98.67 Mn by 2033.

Q.2. What is the estimated growth rate (CAGR) of the global bronchiolitis obliterans syndromemarket?

The global bronchiolitis obliterans syndromemarket has an estimated annual growth rate of 5.1% .

Q.3. What are the recent trends of bronchiolitis obliterans syndromemarket?

Emphasis on research and development and collaborations and partnershipsare some of the major trends of the market that is projected to boost the market growth in the near future.

Q.4. Which are the top companies to hold the market share in bronchiolitis obliterans syndrome?

The major companies profiled in this report include AstraZeneca, Allergan, Cipla Inc., Endo International plc, GlaxoSmithKline plc., Johnson & Johnson Private Limited, Lily, Merck KGaA, Novartis AG, Pfizer Inc., Purdue Pharma L.P., Sanofi, Sumitomo Corporation, Teva Pharmaceutical Industries Ltd., among others.

Q.5. Which is the largest regional market in the bronchiolitis obliterans syndrome?

North America is the largest regional market for bronchiolitis obliterans syndrome.